Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)~* The decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study~* Patients with diabetes mellitus requiring insulin therapy for whom the physician has decided to start treatment with Ryzodeg®~* Male or female, no age limitation~Exclusion Criteria:~* Patients who are or have previously been treated with Ryzodeg®~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Patients with a history of hypersensitivity to study product components~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- insulin degludec/insulin aspart (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).